JP2008515971A - 閉塞性動脈疾患のためのスルホンアミドぺリ置換二環式化合物 - Google Patents

閉塞性動脈疾患のためのスルホンアミドぺリ置換二環式化合物 Download PDF

Info

Publication number
JP2008515971A
JP2008515971A JP2007536680A JP2007536680A JP2008515971A JP 2008515971 A JP2008515971 A JP 2008515971A JP 2007536680 A JP2007536680 A JP 2007536680A JP 2007536680 A JP2007536680 A JP 2007536680A JP 2008515971 A JP2008515971 A JP 2008515971A
Authority
JP
Japan
Prior art keywords
group
mmol
compound
room temperature
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007536680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515971A5 (enExample
Inventor
ジャスバー シング
マーク ガーネイ
ジョルジェタ ヘートガン
ペン ユ
デービット ゼンボーワー
ニアン ツォー
Original Assignee
デコード ジェネティクス イーエイチエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デコード ジェネティクス イーエイチエフ filed Critical デコード ジェネティクス イーエイチエフ
Publication of JP2008515971A publication Critical patent/JP2008515971A/ja
Publication of JP2008515971A5 publication Critical patent/JP2008515971A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
JP2007536680A 2004-10-12 2005-06-27 閉塞性動脈疾患のためのスルホンアミドぺリ置換二環式化合物 Pending JP2008515971A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61817204P 2004-10-12 2004-10-12
PCT/US2005/023009 WO2006044000A1 (en) 2004-10-12 2005-06-27 Sulfonamide pert-substituted bicyclics for occlusive artery disease

Publications (2)

Publication Number Publication Date
JP2008515971A true JP2008515971A (ja) 2008-05-15
JP2008515971A5 JP2008515971A5 (enExample) 2008-08-14

Family

ID=35229642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007536680A Pending JP2008515971A (ja) 2004-10-12 2005-06-27 閉塞性動脈疾患のためのスルホンアミドぺリ置換二環式化合物

Country Status (16)

Country Link
US (2) US7598397B2 (enExample)
EP (1) EP1812388B1 (enExample)
JP (1) JP2008515971A (enExample)
KR (1) KR20070091607A (enExample)
CN (1) CN101142184A (enExample)
AT (1) ATE499344T1 (enExample)
AU (1) AU2005296305A1 (enExample)
BR (1) BRPI0516003A (enExample)
CA (1) CA2583667A1 (enExample)
DE (1) DE602005026553D1 (enExample)
IL (1) IL182488A0 (enExample)
MX (1) MX2007004525A (enExample)
NO (1) NO20072288L (enExample)
NZ (1) NZ554491A (enExample)
RU (1) RU2403240C2 (enExample)
WO (1) WO2006044000A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013010712A (ja) * 2011-06-29 2013-01-17 Kotobuki Seiyaku Kk 三環性化合物及びそれを含有する医薬組成物
JPWO2012161071A1 (ja) * 2011-05-20 2014-07-31 日本曹達株式会社 含窒素ヘテロ環化合物および農園芸用殺菌剤

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715921B1 (en) * 2003-09-25 2013-04-24 Abraxis BioScience, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
DE602005026553D1 (de) * 2004-10-12 2011-04-07 Decode Genetics Ehf Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
CN101076531A (zh) * 2004-10-12 2007-11-21 解码遗传学公司 用于阻塞性血管疾病的羧酸迫位取代的双环化合物
TW200740435A (en) * 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
US20080125477A1 (en) * 2006-05-16 2008-05-29 Decode Genetics, Ehf. 7-(acryloyl) indole compositions and methods of making and using same
CA2652152A1 (en) * 2006-05-16 2007-11-29 Decode Genetics Ehf Process for preparing 7-(acryloyl)indoles
WO2007143825A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008127274A2 (en) * 2006-09-22 2008-10-23 Ptc Therapeutics, Inc. Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
TW200843739A (en) * 2007-03-30 2008-11-16 Shionogi & Co Novel pyrrolinone derivative and composition containing the same
EP2219648A4 (en) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
PE20110946A1 (es) * 2008-11-21 2012-01-05 Iroko Cardio Llc Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia
WO2014005274A1 (zh) * 2012-07-03 2014-01-09 海南卫康制药(潜山)有限公司 多取代的8-氮杂环【3.2.1】辛烷化合物
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer
WO2020008317A1 (en) * 2018-07-03 2020-01-09 Janssen Pharmaceutica Nv Acylsufonamide compounds useful as ep3 receptor antagonists
CN112552450A (zh) * 2019-09-10 2021-03-26 天津大学 一种单离子交替共聚物锂盐及其制备方法
WO2024206284A2 (en) * 2023-03-27 2024-10-03 Rutgers, The State University Of New Jersey Therapeutic compounds
CN119100992B (zh) * 2023-06-02 2025-09-16 帕潘纳(北京)科技有限公司 一种特戈拉赞中间体及其衍生物的制备方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4857987A (enExample) * 1971-11-29 1973-08-14
JPH05345778A (ja) * 1991-10-24 1993-12-27 Lilly Ind Ltd 薬剤組成物
JPH06297860A (ja) * 1993-04-14 1994-10-25 New Oji Paper Co Ltd 感熱記録体
WO1996010569A1 (en) * 1994-09-30 1996-04-11 Nippon Chemiphar Co., Ltd. Quinoline derivative
WO1997005091A1 (en) * 1995-07-26 1997-02-13 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives and drugs comprising the same as active ingredients
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO1999000372A1 (fr) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfamides et leur utilisation medicale
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
WO2002016311A1 (en) * 2000-08-22 2002-02-28 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
JP2002528413A (ja) * 1998-10-23 2002-09-03 メルク フロスト カナダ アンド カンパニー Ｅ型プロスタグランジンリガンド及びｃｏｘ−２選択的阻害剤を含む配合剤及び使用方法
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
GB8927981D0 (en) * 1989-12-11 1990-02-14 Ici Plc Carbamoyl derivative
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
EP0511477B1 (en) * 1991-03-11 1996-07-10 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
CN1209809A (zh) * 1996-01-22 1999-03-03 藤泽药品工业株式会社 新化合物
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
ZA984040B (en) * 1997-05-15 1998-11-20 Ono Pharmaceutical Co Benzenesulfonamide compounds
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US6242493B1 (en) * 1998-03-13 2001-06-05 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
TWI314457B (enExample) 2001-03-19 2009-09-11 Shionogi & Co
DE602005026553D1 (de) * 2004-10-12 2011-04-07 Decode Genetics Ehf Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
US20080125477A1 (en) * 2006-05-16 2008-05-29 Decode Genetics, Ehf. 7-(acryloyl) indole compositions and methods of making and using same

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4857987A (enExample) * 1971-11-29 1973-08-14
JPH05345778A (ja) * 1991-10-24 1993-12-27 Lilly Ind Ltd 薬剤組成物
JPH06297860A (ja) * 1993-04-14 1994-10-25 New Oji Paper Co Ltd 感熱記録体
WO1996010569A1 (en) * 1994-09-30 1996-04-11 Nippon Chemiphar Co., Ltd. Quinoline derivative
WO1997005091A1 (en) * 1995-07-26 1997-02-13 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives and drugs comprising the same as active ingredients
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO1999000372A1 (fr) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfamides et leur utilisation medicale
JP2002528413A (ja) * 1998-10-23 2002-09-03 メルク フロスト カナダ アンド カンパニー Ｅ型プロスタグランジンリガンド及びｃｏｘ−２選択的阻害剤を含む配合剤及び使用方法
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
WO2002016311A1 (en) * 2000-08-22 2002-02-28 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012161071A1 (ja) * 2011-05-20 2014-07-31 日本曹達株式会社 含窒素ヘテロ環化合物および農園芸用殺菌剤
US9060517B2 (en) 2011-05-20 2015-06-23 Nippon Soda Co., Ltd. Nitrogenated heterocyclic compound and agricultural or horticultural fungicide
JP2013010712A (ja) * 2011-06-29 2013-01-17 Kotobuki Seiyaku Kk 三環性化合物及びそれを含有する医薬組成物

Also Published As

Publication number Publication date
RU2403240C2 (ru) 2010-11-10
NZ554491A (en) 2009-07-31
DE602005026553D1 (de) 2011-04-07
EP1812388A1 (en) 2007-08-01
CN101142184A (zh) 2008-03-12
IL182488A0 (en) 2007-09-20
WO2006044000A1 (en) 2006-04-27
ATE499344T1 (de) 2011-03-15
US20090291948A1 (en) 2009-11-26
CA2583667A1 (en) 2006-04-27
EP1812388B1 (en) 2011-02-23
NO20072288L (no) 2007-06-25
RU2007115410A (ru) 2008-11-10
US20060079520A1 (en) 2006-04-13
BRPI0516003A (pt) 2008-04-29
MX2007004525A (es) 2007-09-19
US7598397B2 (en) 2009-10-06
KR20070091607A (ko) 2007-09-11
AU2005296305A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
US20090291948A1 (en) Sulfonamide peri-substituted bicyclics for occlusive artery disease
CN1812973B (zh) 可用作蛋白激酶抑制剂的吲唑化合物
KR100295128B1 (ko) 인돌로일구아니딘유도체
CZ28895A3 (en) 2-thioindole, 2-indolinethione and polysulfide compounds, 2-selenoindole, 2-indolineselenone and selenide compounds and pharmaceutical preparations based thereon
US7968718B2 (en) Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
JPWO2002070486A1 (ja) Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物
WO2010044543A2 (ko) 단백질 키나제 억제제로서 헤테로사이클릭 화합물
WO2010080481A1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
NZ538031A (en) Indoles having anti-diabetic activity
US20090075985A1 (en) Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
WO2021145655A1 (ko) 신규한 피라졸 유도체
JP3162572B2 (ja) インドロイルグアニジン誘導体
JP2008515981A (ja) 閉塞性動脈疾患のためのカルボン酸ペリ置換二環式化合物
WO2006108040A1 (en) Substituted indoles and their use as integrin antagonists
WO2019039905A1 (ko) 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물
WO2025037871A1 (ko) 트리사이클릭 화합물 및 이의 mat2a 저해제 용도
CN1972938A (zh) 环状胺化合物
HK1096385B (en) Indazole compounds useful as protein kinase inhibitors
HK1110580B (en) Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110804

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120124